Cargando…
Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation
Peroxisome proliferator-activated receptor γ (PPARγ) is a major therapeutic target for the treatment of type 2 diabetes. However, the use of PPARγ-targeted drugs, such as rosiglitazone and pioglitazone, is limited owing to serious side effects caused by classical agonism. Using a rational drug disco...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6671948/ https://www.ncbi.nlm.nih.gov/pubmed/31371757 http://dx.doi.org/10.1038/s41598-019-47672-w |